RxDoctor Payments DataLook up a doctor →

Rajiv Dhand, MD

Pulmonary Disease · Knoxville, TNNPI 1538118872

Payments from drug & device makers

$426,351in general payments, 2019–2025

Across 414 payments — averaging $1029.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mylan Specialty L.p.$348K
  • Boehringer Ingelheim$34K
  • Astrazeneca UK Limited$14K
  • AstraZeneca$8K
  • Genentech USA, Inc.$7K
  • Teva Pharmaceuticals USA, Inc.$6K
  • plus $10K from 40 others
$128,250in research payments, 2019–2025

Across 4 payments — averaging $32,063 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Mylan Specialty L.p.$128K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$426,351 in reported general payments places this provider in the 95th percentile of 339 pulmonary disease providers in Tennessee.

See all pulmonary disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$19,586
Medicare patients
98
Services billed
205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →